

Idiopathic Nonhistaminergic Acquired Angioedema Versus Hereditary Angioedema



Noémi András, MD, Nóra Veszeli, MSc, Kinga Viktória Kóhalmi, MD, Dorottya Csuka, PhD, György Temesszentandrás, MD, Lilian Varga, PhD, and Henriette Farkas, MD, PhD, DSc Budapest, Hungary

What is already known about this topic? The current classification of angioedema without wheals distinguishes 4 acquired and 3 hereditary forms of the disease. Idiopathic nonhistaminergic acquired angioedema (InH-AAE) and hereditary angioedema with unknown origin (U-HAE) could be difficult to diagnose.

What does this article add to our knowledge? This is the first study comparing the clinical symptoms of InH-AAE and U-HAE seen in 2 separate patient populations with those of C1-INH-HAE.

How does this study impact current management guidelines? The clinical pictures of InH-AAE and U-HAE were similar; however, these 2 disease forms were different from C1-INH-HAE, but the disease burden was similar in these 3 types of angioedema.

BACKGROUND: The mechanism of idiopathic nonhistaminergic acquired angioedema (InH-AAE) has not yet been precisely elucidated. This condition is characterized by recurrent angioedema without wheals.

OBJECTIVE: To study the clinical features of InH-AAE, and to make, for the first time, independent comparisons with hereditary angioedema of unknown origin (U-HAE), as well as with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE).

METHODS: We compared the clinical parameters of 46 patients with InH-AAE with those of 27 patients suffering from U-HAE, as well as of 73 patients with C1-INH-HAE.

RESULTS: The mean age at the onset of symptoms was 36 years in InH-AAE, 13 years in C1-INH-HAE, and 29 years in U-HAE. More than 12 edematous episodes occurred over a year in 56% of patients with InH-AAE, in 59% of those with C1-INH-HAE,

and in 48% of those with U-HAE. Edema of the extremities, of the upper airways, and of the gastrointestinal tract was more common in patients with C1-INH-HAE (92%, 51%, and 75%, respectively). These manifestations occurred less frequently in patients with InH-AAE (54%, 28%, and 20%) and in patients with U-HAE (37%, 29%, and 20%). By contrast, facial edema occurred in only 15% of patients with C1-INH-HAE, but in 67% of patients with InH-AAE and in 59% of patients with U-HAE.

CONCLUSIONS: The clinical manifestations of patients with InH-AAE were different from those of patients with C1-INH-HAE. This may indicate different processes underlying edema formation in these disease forms. The close resemblance of the clinical manifestations in InH-AAE and U-HAE might suggest a similarity between the pathophysiology of these conditions. © 2018 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2018;6:1205-8)

Key words: Angioedema without wheals; Nonhistaminergic angioedema; Hereditary angioedema; Idiopathic angioedema; Clinical characteristic; Angioedematous attack

Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

No funding was received for this work.

Conflicts of interest: N. Veszeli has received travel grants from CSL Behring. K. V. Kóhalmi has received travel grants from CSL Behring and Shire. D. Csuka has received travel grants from CSL Behring, Shire Human Genetic Therapies Inc., and Viropharma. L. Varga has received travel grants from CSL Behring and Shire Human Genetic Therapies Inc. H. Farkas has received honoraria and travel grants from CSL Behring, Shire, Swedish Orphan Biovitrum, and Pharming; and/or served as a consultant for these companies and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, and Shire. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication October 24, 2017; revised April 9, 2018; accepted for publication April 17, 2018.

Available online April 30, 2018.

Corresponding author: Henriette Farkas, MD, PhD, DSc, Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Kutvolgyi ut 4, Budapest 1125, Hungary. E-mail: farkas.henriette@med.semmelweis-univ.hu.

2213-2198

© 2018 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2018.04.018>

Angioedema is nonpruritic and nonpitting swelling of the subcutaneous and/or submucosal tissues.¹ Recurrent angioedema may be accompanied by—or occur without—wheals.^{2,3} Angioedema without wheals occurs in various clinical entities.² A form of the latter, idiopathic nonhistaminergic acquired angioedema (InH-AAE) may entail severe complications.^{4,5} Nevertheless, neither its pathophysiology has been elucidated, nor its proper therapy defined. The diagnosis of InH-AAE can be established by taking a meticulous medical history, by excluding other disorders associated with angioedema of known etiology, and by ascertaining the failure of antihistamine therapy.⁶ Currently, no specific laboratory parameter or test exists to establish the diagnosis of InH-AAE.⁷

The classification of angioedema without wheals distinguishes 4 acquired and 3 hereditary forms of the disease.² The acquired

Abbreviations used

C1-INH-HAE- Hereditary angioedema with C1-inhibitor deficiency
FXII-HAE- Hereditary angioedema with factor XII mutation
HAE- Hereditary angioedema
InH-AAE- Idiopathic nonhistaminergic acquired angioedema
U-HAE- Hereditary angioedema of unknown origin

forms comprise acquired angioedema with C1-inhibitor deficiency, acquired angioedema related to angiotensin converting enzyme inhibitors, idiopathic histaminergic acquired angioedema, and InH-AAE—the subject of our study.² The most common of the 3 hereditary forms is angioedema with impaired activity or deficiency of the C1-inhibitor (C1-INH-HAE). The second, much less common form is hereditary angioedema (HAE) with mutation of the gene of the coagulation factor XII (FXII-HAE).^{8,9} A proportion of patients cannot be classified into these categories, and therefore, they are identified as suffering from hereditary angioedema of unknown origin (U-HAE).² Very recently, novel mutations in the plasminogen (*PLG*) and in the angiotensin 1 (*ANGPT1*) genes have been described in families previously diagnosed with U-HAE, showing that this group of HAE could contain people suffering from the same symptoms, but with different mechanism.^{10,11}

The aim of our study was to explore the clinical picture of InH-AAE in a patient population that has not been subject to research so far and, therefore, has not been discussed in publications. In addition, we intended to compare the features of this disorder with those of C1-INH-HAE (a known bradykinin-mediated inherited disease) and U-HAE (another form of HAE with unknown etiology).

METHODS**Patients**

In the patient population managed at the Hungarian Angioedema Center between 2009 and 2015, we diagnosed 46 patients with InH-AAE, as well as 27 patients with U-HAE (Table I). We reviewed the clinical records of these patients retrospectively. The study protocol was approved by the institutional review board of Semmelweis University of Budapest, and informed consent was obtained from the participants in accordance with the Declaration of Helsinki.

We established the diagnosis of HAE based on the recurrence of its symptoms in first- or second-degree relatives. The diagnostic evaluation of angioedema was followed by complement testing. C1-INH deficiency was diagnosed by demonstrating a C1-INH functional level less than 50% together with a low C4 level. If the patient had low C1-INH function and low C1-INH concentration, the diagnosis was HAE with C1-INH deficiency type I. If a patient had low C1-INH function with a normal or elevated C1-INH concentration, C1-INH-HAE type II was diagnosed. When C1-INH deficiency was accompanied by a negative family history and a normal C1q level, the presence of *de novo* mutations in the *SERPING1* confirmed the diagnosis of C1-INH-HAE. If the complement profile was ambiguous, mutation analysis of the *SERPING1* gene was performed in all cases. If the complement assays did not confirm C1-INH deficiency, the patients were categorized according to their family history. In case of a positive family history for angioedema, HAE with normal C1-INH function was the diagnosis.⁷ Testing for mutations in the *F12* gene assisted further classification and afforded a diagnosis of FXII-HAE.^{8,12} If hereditary disease forms with a known etiology could be excluded, the patients were classified into the group

suffering from U-HAE.³ The following laboratory tests were performed to identify the underlying cause of the disease: complete blood count, clinical chemistry, complement screen, thyroid hormone levels, antithyroid antibody levels, food and inhaled allergen panel (total and specific IgE), and an autoimmune battery of tests. Additional virus and postinfection serology tests, screening for possible foci of inflammation, and stool analysis were performed if necessary. When the etiology of angioedema could not be identified, a known HAE-inducing gene mutation was not found, familial clustering of the disease was missing, and antihistamine therapy with second-generation antihistamines was ineffective in preventing recurrence, the patient was diagnosed with InH-AAE.

Methods

C1-inhibitor activity was measured with a commercially available ELISA kit. Radial immunodiffusion was applied to determine C1-inhibitor concentration. C4 and C3 complement levels were determined by nephelometry. Anti-C1-INH-Ig (A, G, M) levels were quantified with an in-house ELISA method. Mutations of the *F12* gene were identified by PCR amplification followed by Sanger sequencing.⁸ The antihistamine was considered ineffective when there was a lack of effect from chronic, high-dose antihistamine therapy (cetirizine at 40 mg/day or equivalent) administered over at least 1 month, possibly associated with an interval during which 3 or more attacks of angioedema occurred. The same applied to cases where conventional treatment (with antihistamines, glucocorticoids, or epinephrine, occasionally) failed to relieve the symptoms rapidly or achieved only partial relief.^{7,13,14}

We compared the clinical parameters of the InH-AAE and U-HAE groups with each other, as well as with those of 73 age- and sex-matched patients with C1-INH-HAE. Different demographical data were studied. We recorded mean age at the time of the onset of symptoms/time of diagnosis and then compared these data among the 3 groups. We determined the mean number of edematous episodes occurring over a year in the studied disease forms. We analyzed the locations of the attacks reported by the subjects so far. As performing an otorhinolaryngology examination was not possible in a proportion of cases and, hence, the exact location of edema formation could not be determined, the umbrella term “upper airway edema” was used to include pharyngeal, laryngeal, and hypopharyngeal edema. In such cases, upper airway edema was suspected based on the suggestive symptoms and clinical signs (dysphagia, lump sensation in the throat, feeling of tightness, voice changes, resonant “barky” cough, stridor, dyspnea, aphonia).^{15,16} Furthermore, facial edema was distinguished from the swelling of the lips or tongue to map the symptoms more accurately. In patients with C1-INH-HAE, these data were available from the registry of the Hungarian Angioedema Center: the archived patient diaries contain accurate data on the frequency and location of edematous symptoms. In the other 2 study groups, these data were obtained from medical records, or from the patients themselves. On registration with the Hungarian Angioedema Center, every patient completes a standardized questionnaire on the disease symptoms experienced, and the medical history is obtained according to a standardized protocol. Previous hospitalizations are recorded accurately. The questions identify any possible familial clustering and record the medications taken by the patient along with the characteristics of the edematous episodes.

RESULTS

Symptoms first occurred in patients with InH-AAE at the age of 36 years on average. In the U-HAE group, the onset of

TABLE 1. Demographical properties of the 3 studied groups of angioedema types

| | No. of patients (n) | Mean age at the onset of symptoms, y (min.-max.) | Mean age at the time of diagnosis, y (min.-max.) | No. of females/males (n) |
|------------|---------------------|--|--|--------------------------|
| InH-AAE | 46 | 36 (8-48) | 41 (11-81) | 39/7 |
| U-HAE | 27 | 29 (2-82) | 36 (6-88) | 21/6 |
| C1-INH-HAE | 73 | 13 (1-45) | 28 (1-69) | 60/13* |

C1-INH-HAE, Hereditary angioedema with C1-inhibitor deficiency; *InH-AAE*, idiopathic nonhistaminergic acquired angioedema; *U-HAE*, hereditary angioedema of unknown origin.

*Patients in the C1-INH-HAE group were sex- and age-matched with those in the other 2 groups, and therefore, this value is nonrepresentative.




FIGURE 1. **A**, Distribution of patients by the annual number of attacks classified into 3 groups (≥ 12 , 6-11, or 1-5) in the studied 3 types of angioedema. **B**, The prevalence of different attack locations in the studied groups of angioedema. *C1-INH-HAE*, Hereditary angioedema with C1-inhibitor deficiency; *InH-AAE*, idiopathic nonhistaminergic acquired angioedema; *U-HAE*, hereditary angioedema of unknown origin.

symptoms was somewhat earlier, but still in adulthood. Patients with C1-INH-HAE began to experience symptoms in their childhood. The ranking was the same with respect to the time of diagnosis. The mean latency period until diagnosis was 6 to 7 years in the InH-AAE and U-HAE groups. In the C1-INH-HAE group, however, it was 15 years on average after the onset of symptoms. This suggests that the diagnosis of angioedema is delayed, even if the appropriate diagnostic modalities are available.¹⁷ Women predominated both in the InH-AAE and U-HAE groups (see Table 1).

The mean duration of follow-up was 4 years (0.3-19 years) in the InH-AAE group, on average 7 years (0.25-39 years) in the U-HAE group, and 7 years (1-25 years) in the case of the 73 patients with C1-INH-HAE. The cumulative number of edematous episodes reported by the patients was 7,609 in the InH-AAE

group (n = 46), 3,320 in the U-HAE group (n = 27), and 11,676 in age- and sex-matched patients with C1-INH-HAE (n = 73). By considering the mean annual frequency of edematous attacks, we classified patients into the following categories: infrequent attacks (1-5 per year), moderately frequent attacks (6-11 per year), and frequent attacks (≥ 12 per year). In all 3 groups, approximately half of the patients reported frequent attacks (Figure 1, A).

With regard to the location of symptoms, edema of the extremities was reported by 54% of the patients in the InH-AAE, and by 37% in the U-HAE groups, but by as many as 92% of patients with C1-INH-HAE. Sixty-seven percent of patients with InH-AAE, 59% of patients with U-HAE, and 15% of patients with C1-INH-HAE experienced facial edema (not including edema of the lips) during their lives. Edema of the tongue and lips occurred in 65% of patients with InH-AAE, in 55% of patients with U-HAE, and in 21% of patients with C1-INH-HAE. Upper airway edema was documented in only approximately 30% of patients with InH-AAE and of patients with U-HAE, but in 51% of patients with C1-INH-HAE. Gastrointestinal edema was reported by nearly 20% of patients in the InH-AAE and U-HAE groups; by contrast, this occurred in 75% of patients with C1-INH-HAE (Figure 1, B).

DISCUSSION

Our study was a pioneering Hungarian patient survey that analyzed the clinical features of InH-AAE and U-HAE. Compared with previous studies,^{3,18-20} it was the first to analyze data from a larger subset of HAE patients with U-HAE separately from those with FXII-HAE, and by making comparisons with an age- and sex-matched group of patients with C1-INH-HAE.

We compared 3 types of angioedema. Two of these, InH-AAE and U-HAE, are idiopathic disorders—their mechanism is still incompletely clarified.² The third type was hereditary—bradykinin-mediated angioedema with C1-inhibitor deficiency.²¹ The analysis and comparison of the clinical features of these disorders could yield clues about their pathophysiology.

The clinical manifestations of these 3 groups of diseases outline a trend. Angioedema symptoms occur earliest in patients with C1-INH-HAE. Patients with U-HAE begin to experience symptoms during their young adulthood, and angioedema appears latest in patients with InH-AAE. With regard to the frequency of the symptoms, we can conclude that the patients with the 2 idiopathic disease forms experience edema as often as do patients with C1-INH-HAE. This underlines the importance of monitoring these patients, because their disease burden is similar to that of patients with C1-INH-HAE.

Both in patients with InH-AAE and in those with U-HAE, edema most often involved the face and tongue. We found that in

contrast with earlier findings (75.6%), only 15% of patients with C1-INH-HAE experienced facial edema; this discrepancy might resulted from the separation of lip/tongue and upper airway edemas from facial edema in our investigation.²² Gastrointestinal edema, which is among the most characteristic locations in C1-INH-HAE, was less typical in InH-AAE and in U-HAE. In this respect, therefore, U-HAE is more akin to the acquired disease form. A possible reason for this may be that some patients currently belonging to the InH-AAE group carry a genetic defect, and can thus pass on the disease to yet another generation. In this case, their offspring or grandchildren may be classified into the U-HAE group, based on the familial clustering of symptoms. Also in C1-INH-HAE, it is known that familial clustering is absent in 25% of diagnosed cases, where the deficiency of C1-INH is hereditary—caused by a *de novo* mutation.²³

Our results are in agreement with previous experience on the clinical features of the disease, in regard of mean age at the onset, as well as of symptom frequency and location. On the other hand, an earlier study did not found a different female-to-male ratio among patients with InH-AAE.³ However, our findings show considerable female predominance both in the InH-AAE and in the U-HAE group. This is in contrast with the population of patients with C1-INH-HAE, in which the ratio of males and females is approximately 50%/50%.²⁴ Similar to our findings, a previous study described a higher proportion of females in the U-HAE group.²⁵ This difference may suggest a role for female sex hormones and for hormonal contraceptives. The efficacy of estrogen on edematous attacks has already been described in the U-HAE group.²⁶

According to the studies by Mansi et al,³ and by our work group, data from more than 1000 patients confirm that in InH-AAE, the time of the initial onset and the location of the symptoms are different from those seen in C1-INH-HAE. Based on these differences, the occurrence of edema may be attributed to different mechanisms in these 2 disease forms. On the other hand, the similarities between InH-AAE and purely U-HAE groups in these aspects may suggest similar pathophysiological processes behind the symptoms.

In our current survey, we followed the international classification of angioedema published in 2014.² Considering the expansion of therapeutic options, a proportion of patients with angioedema unresponsive to high-dose antihistamines might respond to other treatments of proven efficacy in urticaria, such as omalizumab, or immunomodulation therapy such as ciclosporin A.²⁷ This fact may serve as the basis for extending the criteria for belonging to the InH-AAE population. In particular, it should be stated that the agents mentioned above would also be ineffective once treatment with high-dose antihistamines had failed. The classification of angioedema without wheals into various categories keeps changing dynamically, because new mechanisms have been elucidated in the background of angioedema hitherto identified as a disease form of unknown etiology. This is exemplified by the discovery of 2 new mutations in the U-HAE population (see the Addendum section). In view of the foregoing, revisiting and updating the classification of “angioedema without wheals” would be opportune.

ADDENDUM

After the submission of our manuscript, new types of HAE (HAE with plasminogen mutation and HAE with angiotensin II gene mutation) were published. As it is possible that some of our patients with U-HAE also carry these mutations, we have introduced screening for the latter.^{10,11}

REFERENCES

- Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. *Int Immunopharmacol* 2003;3:311-7.
- Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. *Allergy* 2014;69:602-16.
- Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. *J Intern Med* 2015;277:585-93.
- Azofra J, Diaz C, Antepara I, Jauregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. *Ann Allergy Asthma Immunol* 2015;114:418-419.e1.
- Stahl MC, Harris CK, Matto S, Bernstein JA. Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement. *J Allergy Clin Immunol Pract* 2014;2:818-9.
- Cicardi M, Bergamaschini L, Zingale LC, Goffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. *Am J Med* 1999;106:650-4.
- Farkas H, Veszeli N, Kajdacs E, Cervenak L, Varga L. “Nuts and Bolts” of laboratory evaluation of angioedema. *Clin Rev Allergy Immunol* 2016;51:140-51.
- Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. *Biochem Biophys Res Commun* 2006;343:1286-9.
- Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. *Am J Hum Genet* 2006;79:1098-104.
- Bork K, Wulff K, Steinmuller-Magin L, Braenne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogen gene. *Allergy* 2018;73:442-50.
- Bafunno V, Firinu D, D’Apolito M, Cordisco G, Loffredo S, Leccese A, et al. Mutation of the angiotensinogenase-1 gene (ANGPT1) associates with a new type of hereditary angioedema. *J Allergy Clin Immunol* 2018;141:1009-17.
- Gosswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. *Cytogenet Genome Res* 2008;121:181-8.
- Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, et al. Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. *Allergy Asthma Proc* 2012;33:S145-56.
- James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. *Expert Opin Pharmacother* 2017;18:253-62.
- Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. *Allergy* 2007;62:842-56.
- Farkas H. Management of upper airway edema caused by hereditary angioedema. *Allergy Asthma Clin Immunol* 2010;6:19.
- Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. *Allergy* 2017;72:300-13.
- Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, et al. Angioedema without urticaria: a large clinical survey. *CMAJ* 2006;175:1065-70.
- Malbran E, Fernandez Romero D, Juri MC, Larrauri BJ, Malbran A. Epidemiology of angioedema without wheals in an allergy and immunology center. *Medicina* 2015;75:273.
- Wintemberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. *Clin Exp Immunol* 2014;178:112-7.
- Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. *Int Arch Allergy Immunol* 2014;165:119-27.
- Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. *Am J Med* 2006;119:267-74.
- Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. *J Allergy Clin Immunol* 2000;106:1147-54.
- Kaplan AP. Angioedema. *World Allergy Organ J* 2008;1:103-13.
- Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. *Allergy* 2015;70:1004-12.
- Bork K, Wulff K, Witzke G, Stanger C, Lohse P, Hardt J. Antihistamine-resistant angioedema in women with negative family history: estrogens and F12 gene mutations. *Am J Med* 2013;126. 1142.e9-e14.
- Zuberbier T, Aberer W, Asero R, Abdul Latif AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update [published online ahead of print January 15, 2018]. *Allergy*. <https://doi.org/10.1111/all.13397>.